Share this with your friends
What is psychedelic therapy?
Psychedelic therapy is a mode of treatment that uses psychedelic drugs (such as LSD, MDMA, psilocybin, ibogaine, ayahuasca, or others) to enhance the effectiveness of therapy.
Psychedelic therapy is only administered a small number of times, as opposed to traditional drug-based treatments which require patients to take medications every day, sometimes for the rest of their lives. These other treatments often have significant side effects and can result in dependence.
The word “psychedelic” means “mind-manifesting,” and refers to a broad class of naturally occurring and synthetic compounds that expand awareness and facilitate personal, interpersonal, and/or spiritual insights when used carefully in the proper settings.
Government-approved research is showing that psychedelic therapy can help people suffering from serious mental health conditions, especially those for whom other treatments have failed. The world’s largest-ever clinical trial of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) is almost complete, and the results will help make MDMA-assisted psychotherapy the first legal psychedelic treatment by 2021.
Multidisciplinary Association for Psychedelic Studies (MAPS) needs your help to complete this study and legalize psychedelic therapy!
MAPS has already raised over $1.3 million through contributions from individuals, private foundations, and our previous crowdfunding campaign. We’re asking you to help us raise the remaining $50,000.
To make a donation and share this campaign, you will help:
- Make MDMA-assisted psychotherapy a legal treatment by 2021
- Complete a crucial study of MDMA-assisted psychotherapy for veterans, firefighters, and police officers with PTSD
- Demonstrate growing public support for psychedelic and medical marijuana researchLegalizing psychedelic therapy is not the same as legalizing psychedelics for all uses. We are completing the research necessary to develop psychedelic therapy into a legal prescription treatment.
- Psychedelic therapy is not a take-home drug. Psychedelic therapy must be conducted in a therapeutic environment with proper support.
Legalizing psychedelic therapy is not the same as legalizing psychedelics for all uses. We are completing the research necessary to develop psychedelic therapy into a legal prescription treatment.
Psychedelic therapy is not a take-home drug. Psychedelic therapy must be conducted in a therapeutic environment with proper support.
MAPS’ non-profit drug development research needs support because neither the pharmaceutical industry, the government, nor major foundations have yet been willing to invest in psychedelic therapy research.
MDMA-assisted psychotherapy combines talk therapy with the use of MDMA, a drug that may enhance the effectiveness of psychotherapy for PTSD.
MDMA (3,4-methylenedioxymethamphetamine) is a synthetic compound that may increase the effectiveness of psychotherapy by strengthening the alliance between therapist and patient, and helping subjects feel more comfortable discussing difficult memories and emotions.
In a recently published study , 83% of subjects receiving MDMA-assisted psychotherapy no longer qualified for PTSD, and everyone who received a placebo and then went on to receive MDMA-assisted psychotherapy experienced significant and lasting improvements. Primarily female survivors of sexual assault and abuse, these subjects had suffered from PTSD for an average of 19 years.
This is the most important study in MAPS international research program to develop MDMA-assisted psychotherapy into a prescription treatment for PTSD.
- By making a gift and sharing this campaign, you’re helping make psychedelic therapy a legally available treatment.
- Every gift—no matter the size—makes a difference.
MAPS is offering lots of unique, limited-quantity perks—Tom Shroder’s ACID TEST, vinyl stickers, custom pendants, an online webinar, chances to meet the researchers, and more.